Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 3/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022263 | 0.94 | MAPK9 (0.54) | MAPK9MAPK10HDAC8MAPK8FLT3 | |
| SCHEMBL15022987 | 0.80 | MAPK9 (0.51) | MAPK9MAPK10MAPK8FLT3NR3C2 | |
| SCHEMBL25611895 | 0.78 | FLT3 (0.61) | MAPK9MAPK10MAPK8FLT3NR3C2 | |
| SCHEMBL15022988 | 0.78 | MAPK9 (0.59) | MAPK9MAPK10MAPK8FLT3NR3C2 | |
| SCHEMBL3272118 | 0.78 | MAPK9 (0.59) | MAPK9MAPK10MAPK8FLT3NR3C2 | |
| SCHEMBL27315071 | 0.78 | MAPK9 (0.68) | MAPK9MAPK10MAPK8FLT3NR3C2 | |
| SCHEMBL15022094 | 0.75 | HDAC8 (0.44) | MAPK9MAPK10HDAC8FLT3EGLN2 | |
| SCHEMBL13734778 | 0.74 | CHKA (0.56) | MAPK9MAPK10MAPK8FLT3NR3C2 | |
| SCHEMBL15022086 | 0.74 | MAPK9 (0.50) | MAPK9MAPK10MAPK8FLT3NR3C2 | |
| SCHEMBL15022984 | 0.73 | HDAC8 (0.46) | MAPK9MAPK10HDAC8FLT3EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | CHRNA10, ATXN10, SCN10A | MAPK9 1943/4885MAPK10 61/4885HDAC8 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.